Match tier Listed
Presence Current · Arkansas
Last published 2026
Sources OpenAlex · ORCID
Refreshed 2026-10-05

Japneet Kaur

Postdoctoral fellow

15 h-index 103 pubs 623 cited

  • Humans
  • Animals
  • Cellular Senescence
  • Mice
  • Osteocytes
  • Female
  • Male
  • Aging
  • Bone and Bones
  • Signal Transduction
  • Multiple Myeloma
  • Senotherapeutics
  • Bone Neoplasms
  • Cell Line, Tumor
  • Tumor Microenvironment

Biography and Research Information

OverviewAI-generated summary

Japneet Kaur's research focuses on cellular senescence and its role in age-related disorders, particularly within the skeletal system. Her work investigates the mechanisms of senescence in osteocytes and the potential of senolytic therapies to mitigate age-associated bone conditions. Kaur has contributed to studies examining the effects of both local and systemic senolysis in aged mice, assessing the impact on skeletal health and the broader benefits of clearing senescent cells.

Her research also extends to the in vitro and in vivo effects of specific compounds, such as zoledronic acid, on senescence markers and the associated secretory phenotype. Kaur's scholarship metrics include an h-index of 15, with over 100 publications and more than 600 citations. She has served as a Co-Principal Investigator on a $395,650 NIH grant focused on developing a minimally invasive biomarker assay for delayed radiation injury. Kaur collaborates extensively with researchers at the University of Arkansas for Medical Sciences, including Elena Ambrogini, Aric Anloague, Sharmin Khan, and Hayley M. Sabol.

Metrics

  • h-index: 15
  • Publications: 103
  • Citations: 623

Positions

  • Postdoctoral fellow 2022–present
    University of Arkansas for Medical Sciences Physiology and Cell Biology ORCID
  • Post-doctoral Fellow 2020–2022
    Mayo Clinic Kogod Aging Center ORCID

Selected Publications

  • Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)
    Figshare DOI OpenAlex
  • Additional file 1 of Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)
    Figshare DOI OpenAlex
  • Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)
    Figshare DOI OpenAlex
  • Additional file 1 of Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)
    Figshare DOI OpenAlex
  • Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)
    Journal of Experimental & Clinical Cancer Research DOI OpenAlex
  • Expression of miRNAs associated with Cellular Senescence and Osteoporosis in Bone: Insights from Human Biopsies (2025)
    SSRN Electronic Journal DOI OpenAlex
  • Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition (2025)
    Experimental Hematology and Oncology 3 citations DOI OpenAlex
  • Examination of Skeletal and Senescence Phenotypes in Young Mice with Juvenile Onset Type 1 Diabetes (2025)
    Calcified Tissue International 1 citation DOI OpenAlex
  • Ex Vivo Model Systems of Cancer-Bone Cell Interactions (2025)
    Methods in molecular biology 2 citations DOI OpenAlex
  • Abstract 5099: Notch inhibition as a therapeutic approach to eliminate dormant cancer cells in multiple myeloma (2025)
    Cancer Research DOI OpenAlex

View all publications on OpenAlex →

Federal Grants 1 $395,650 total

NIH Co-PI Feb 2020 - Jan 2026

Development of a minimally invasive biomarker assay to detect delayed radiation injury

NIH Office of the Director $395,650 U01

Collaboration Network

72 Collaborators 21 Institutions 5 Countries

Top Collaborators

View profile →
View profile →
View profile →
View profile →
View profile →
View profile →
View profile →

Similar Researchers

Based on overlapping research topics